[Federal Register Volume 82, Number 30 (Wednesday, February 15, 2017)]
[Notices]
[Pages 10779-10780]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-03016]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the patent applications listed below may be obtained by communicating 
with the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

A Bivalent Conjugate Vaccine for Malaria and Typhoid Prophylaxis

    Description of Technology: Malaria is the single leading cause of 
mortality, especially among children in the developing world. Typhoid 
fever, caused by infection with Salmonella typhi, is known to be 
endemic with malaria and causes its own significant disease burden. 
Scientists at the National Institute of Allergy and Infectious Diseases 
(NIAID), part of the National Institutes of Health, have developed a 
novel bivalent vaccine candidate that may effectively prevent malaria 
and typhoid. This approach significantly enhances immune response to 
the Pfs25 Malaria transmission blocking antigen and produces a robust 
immune response against Salmonella typhi Vi polysaccharide (ViP).
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.
    Potential Commercial Applications:
     Development of this technology into a vaccine may protect 
vulnerable populations from both Malaria transmission and Typhoid 
fever.
    Competitive Advantages:
     This technology has significant advantages over current 
treatments, since there is currently only one commercial Malaria 
vaccine licensed for use in Europe only, which was not developed to 
address Malaria transmission, and the currently licensed Salmonella 
typhi vaccines show incomplete efficacy and do not provide long-term 
immunity. A formulation of the present technology has shown the ability 
to induce an immune response to Pfs25 in excess of 100 times higher and 
Salmonella typhi antigen 20-40 times higher than what is seen by 
immunization with either antigen alone.
    Development Stage:
     In vivo data available (animal).
    Inventors: Drs. Patrick Duffy, Sojung An, and Puthupparampil 
Scaria, NIAID, NIH.
    Publications: None.
    Intellectual Property: Provisional Patent application #62/327,184 
Filed 04/25/16, Technology reference #E-124-2016/0.

[[Page 10780]]

    Licensing Contact: Daniel Anacker, Ph.D., 301-761-7671, 
[email protected].
    Collaborative Research Opportunity: The NIAID, Laboratory of 
Malaria Immunology and Vaccinology is seeking statements of capability 
or interest from parties interested in collaborative research to 
further develop, evaluate, or commercialize this technology. Please 
contact Dr. Daniel Anacker at 301-761-7671 or [email protected] 
for more information.

    Dated: February 8, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-03016 Filed 2-14-17; 8:45 am]
BILLING CODE 4140-01-P